Durvalumab Approved for Endometrial Cancer

  Published 11 months ago

Durvalumab combo treats advanced endometrial cancer; AstraZeneca leads oncology innovation.

  • Durvalumab plus chemo for first-line advanced/recurrent pMMR endometrial cancer.
  • Maintenance therapy combines Durvalumab and olaparib post-chemotherapy.
  • AstraZeneca focuses on oncology, cardiovascular, renal, and rare diseases.

You might like these

Exicom Announces Rights Issue & Debt-to-Equity Move

Modi Hails India’s Economic Rise

KEI Q1 Profit Jumps 30% YoY

Iveco Shares Fall on Tata, Leonardo Deals

India Services PMI Hits 15-Year High

SBI Urges RBI September Rate Cut

Edelweiss Shares Rise on Block Deal

News that matters the most ⚡